top of page

更新

2022年12月29日

Buprenorphine X-Waiver Update from the Substance Abuse and Mental Health Services Administration (SAMHSA)

随着2023年综合拨款法案的签署，国会取消了“DATA-Waiver计划”。

所有 DEA 注册者都应注意以下事项：

  • 使用丁丙诺啡治疗阿片类药物使用障碍的患者不再需要 X-Waiver 注册。

  • 所有丁丙诺啡处方仅需要标准的 DEA 注册号码。
  • 对于处方人员使用丁丙诺啡治疗阿片类药物使用障碍的患者数量没有限制或上限。

您可以在此处找到 SAMHSA 有关这些变化的复杂细节的信息。

2022年11月4日

CDC 疼痛科普阿片类药物处方临床实践指南更新

美国疾病控制与预防中心已更新其《阿片类药物止痛临床实践指南》 。该指南在2016年指南的基础上进行了更新，扩展了支持临床医生和患者的建议，并改善了患者护理和安全。

具体来说， 2022 年临床实践指南旨在帮助临床医生：

  • 改善与患者关于疼痛治疗（包括阿片类药物治疗疼痛）益处和风险的沟通

  • 提高疼痛治疗的安全性和有效性

  • 减轻疼痛

  • 改善疼痛患者的功能和生活质量

  • 降低与阿片类药物疼痛治疗相关的风险（包括阿片类药物使用障碍、过量服用和死亡）

2021年9月7日

全州药物过量安全 (SOS) 工作组行动通知：为继承阿片类药物治疗患者的医疗服务提供者提供最佳实践

加州公共卫生部 (CDPH) 代表全州药物过量安全 (SOS) 工作组及其合作伙伴发布了一份行动通知，以便酌情广泛传播。这份行动通知面向医疗服务提供者，详细说明了在因医疗机构关闭或其他原因而接收接受阿片类药物治疗的患者时，应考虑的最佳做法，并提供可用的支持性资源。这份行动通知由 CDPH、医疗保健服务部 (DHCS)、消费者事务部 (DCA) 和加州医疗委员会 (MBC) 签署。点击此处阅读完整的 CDPH 文章。

​

2021年4月28日

美国卫生与公众服务部关于丁丙诺啡处方的更新

After the false start about the buprenorphine waiver changes in January 2021, we are delighted to share good news: Health and Human Services announced significant updates to the Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder.

 

Here is our summary of these updates, as we best understand it:

  • Who does this apply to: Physicians (MDs and DOs), physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives who have a state license and DEA number.

  • What changed:

    • The new exemption allows eligible practitioners to apply for a waiver and get an X number to treat up to 30 patients with buprenorphine WITHOUT having to do the 8 or 24 hour certification training. All practitioners need to do is submit a form to request a new waiver by following the instructions on this page.

      • If any of the above practitioners wish to prescribe buprenorphine to more than 30 patients, they need to complete the corresponding 8 or 24 hour trainings per the old system and meet certain conditions.

    • The exemption also allows practitioners to prescribe buprenorphine WITHOUT having to certify that they are able to provide counseling or other ancillary services, unless they intend to treat more than 30 patients.

  • When does it go into effect: Immediately, as of 4/28/2021.

  • The goal: Expand access to buprenorphine for opioid use disorder treatment!

  • What does it mean for me as a detailer: You can now encourage providers who only want to treat a small number of patients with buprenorphine to simply submit a waiver request to get started - a much lower lift than spending the weekend in online trainings!

Information from SAMHSA on the intricacies of these changes can be found here: https://www.samhsa.gov/medication-assisted-treatment/become-buprenorphine-waivered-practitioner.

​

bottom of page